Cargando…

Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC

Triple-negative breast cancer (TNBC) is associated with high recurrence rates, high incidence of distant metastases, and poor overall survival (OS). Taxane and anthracycline-containing chemotherapy (CT) is currently the main systemic treatment option for TNBC, while platinum-based chemotherapy showe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrari, Paola, Scatena, Cristian, Ghilli, Matteo, Bargagna, Irene, Lorenzini, Giulia, Nicolini, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836182/ https://www.ncbi.nlm.nih.gov/pubmed/35163586 http://dx.doi.org/10.3390/ijms23031665

Ejemplares similares

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
por: Cerbelli, Bruna, et al.
Publicado: (2017)

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
por: Petrosyan, Varduhi, et al.
Publicado: (2022)

Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
por: Godet, Inês, et al.
Publicado: (2021)

Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
por: Gandhi, Shipra, et al.
Publicado: (2021)

CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients
por: Crucitta, Stefania, et al.
Publicado: (2023)

Special Issue: Molecular Biomarkers in Solid Tumors
por: Fusco, Nicola, et al.
Publicado: (2021)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
por: Singh, Desh Deepak, et al.
Publicado: (2021)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

LC–MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells
por: Estrada-Pérez, Alan Rubén, et al.
Publicado: (2022)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts
por: Mollah, Farhana, et al.
Publicado: (2021)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy
por: He, Jiabei, et al.
Publicado: (2019)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC
por: Brockwell, Natasha K., et al.
Publicado: (2019)

Encapsulation and adhesion of nanoparticles as a potential biomarker for TNBC cells metastatic propensity
por: Merkher, Yulia, et al.
Publicado: (2023)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy
por: Luen, Stephen L., et al.
Publicado: (2019)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022)

Molecular Mechanisms and Biomarkers Associated with Chemotherapy-Induced AKI
por: De Chiara, Letizia, et al.
Publicado: (2022)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq
por: Lanceta, Lilibeth, et al.
Publicado: (2021)

Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report
por: Gomez-Puerto, Diego, et al.
Publicado: (2022)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023)

Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study
por: Scatena, Cristian, et al.
Publicado: (2018)

Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?
por: Sajjadi, Elham, et al.
Publicado: (2020)

Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy
por: Shaath, Hibah, et al.
Publicado: (2021)

Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma
por: Naccarato, Antonio Giuseppe, et al.
Publicado: (2019)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis
por: Provenzano, Leonardo, et al.
Publicado: (2023)

Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC)
por: Chuan, Tian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mq0luu5umkl4c6d598bn0ns99p